CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. AGIOa leader in breakthrough therapies for cellular metabolism in rare diseases, today announced that the company will be presenting at the following investor conferences in March:

• Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 1:30 p.m. ET; And
• Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023 at 12:00 p.m. ET.

Live webcasts of the presentations are available under Events & Presentations under the Investors section of the Company’s website at www.agios.com. Recordings of the webcasts will be archived on the Agios website for a minimum of two weeks after each presentation.

About agios
Agios is a biopharmaceutical company powered by connections. The Agios team maintains strong relationships with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for rare diseases. In the US, Agios is commercializing a premium pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company’s leadership in cellular metabolism, Agios is advancing a robust clinical pipeline of investigational drugs with programs in alpha and beta thalassemia, sickle cell disease, pediatric PK deficiency and MDS-related anemia. In addition to its clinical pipeline, Agios has a PAH stabilizer in preclinical development as a potential treatment for phenylketonuria (PKU) and strong scientific expertise in classical hematology. For more information, visit the company’s website at www.agios.com.

Investor and media contact
Jessica Rennekamp
Senior Director, Corporate Communications
Jessica.Rennekamp@agios.com